Myeloperoxidase in kidney disease

Kidney International

Volumn 64, Issue 6, 2003, Pages 1956-1967

  Malle, Ernst ^b   Buch, Thomas ^b   Grone, Hermann Josef ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NONE

Author keywords

Advanced glycation end products; Chloramines; Glomerulonephritis; Hypochlorous acid hypochlorite; LOX 1; MPO hydrogen peroxide chloride system; Renal disease

Indexed keywords

CHLORIDE; EPITOPE; HYDROGEN PEROXIDE; LIPID; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

BIOCHEMISTRY; CATALYST; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME DEFICIENCY; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERLIPIDEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; KIDNEY PERFUSION; MEMBRANOUS GLOMERULONEPHRITIS; MONONUCLEAR CELL; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPERFUSION INJURY; REVIEW; RODENT; URINALYSIS;

EID: 0344514747     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00336.x     Document Type: Article

References (120)

1. HAMPTON MB, KETTLE AJ, WINTERBOURN CC: Inside the neutrophil phagosome: Oxidants, myeloperoxidase, and bacterial killing. Blood 92:3007-3017, 1998
2. PODREZ EA, ABU-SOUD HM, HAZEN SL: Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28:1717-1725, 2000
3. KETTLE AJ, WINTERBOURN CC: Myeloperoxidase: A key regulator of neutrophil oxidant production. Redox Rep 3:3-15, 1997
4. BROWN KE, BRUNT EM, HEINECKE JW: Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 159:2081-2088, 2001
5. NAGRA RM, BECHER B, TOURTELLOTTE WW, et al: Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78:97-107, 1997
6. DAUGHERTY A, DUNN JL, RATERI DL, HEINECKE JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444, 1994
7. 2/halide system in human atherosclerotic lesions:colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 267:4495-4503, 2000
8. SUGIYAMA S, OKADA Y, SUKHOVA GK, et al: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158:879-891, 2001
9. HAZEN SL, HSU FF, DUFFIN K, HEINECKE JW: Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J Biol Chem 271:23080-23088, 1996
10. HEINECKE JW: Tyrosyl radical production by myeloperoxidase: A phagocyte pathway for lipid peroxidation and dityrosine cross-linking of proteins. Toxicology 177:11-22, 2002
11. WINTERBOURN CC, KETTLE AJ: Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med 29:403-409, 2000
12. MALLE E, HAZELL L, STOCKER R, et al: Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler Thromb Vasc Biol 15:982-989, 1995
13. HAZELL LJ, ARNOLD L, FLOWERS D, et al: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97:1535-1544, 1996
14. MALLE E, WOENCKHAUS C, WAEG G, et al. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 150:603-615, 1997
15. GRÖNE HJ, GRÖNE EF, MALLE E: Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest 82:5-14, 2002
16. CARR AC, MCCALL MR, FREI B: Oxidation of LDL by myeloperoxidase and reactive nitrogen species: Reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20:1716-1723, 2000
17. HAZEN SL, ZHANG R, SHEN Z, et al: Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: Pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 85:950-958, 1999
18. THURAISINGHAM RC, NOTT CA, DODD SM, YAQOOB MM: Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57:1968-1972, 2000
19. SUAREZ-PINZON WL, MABLEY JG, STRYNADKA K, et al: An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. J Autoimmun 16:449-455, 2001
20. ALLEN DA, HARWOOD S, VARAGUNAM M, et al: High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. FASEB J 17:908-910, 2003
21. ε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113, 1999
22. YAMAMOTO Y, KATO I, DOI T, et al: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
23. HILLEGASS LM, GRISWOLD DE, BRICKSON B, ALBRIGHTSON-WINSLOW C: Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 24:285-295, 1990
24. BROUWER E, HUITEMA MG, MULDER AHL, et al: Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 45:1120-1131, 1994
25. CHATTERJEE PK, CUZZOCREA S, BROWN PA, et al: Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 58:658-673, 2000
26. VISSERS MC, WINTERBOURN CC: The effect of oxidants on neutrophil-mediated degradation of glomerular basement membrane collagen. Biochim Biophys Acta 889:277-286, 1986
27. JOHNSON RJ, COUSER WG, CHI EY, et al. New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79:1379-1387, 1987
28. ORMROD DJ, HARRISON GL, MILLER TE: Inhibition of neutrophil myeloperoxidase activity by selected tissues. J Pharmacol Methods 18:137-142, 1987
29. SCHIERWAGEN C, BYLUND-FELLENIUS AC, LUNDBERG C: Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods 23:179-86, 1990
30. 2-halide system in immune complex nephritis. Kidney Int 32:342-349, 1987
31. STEINHOFF J, EINECKE G, NIEDERSTADT C, et al: Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and α2-macroglobulin in the urine. Transplantation 64:443-447, 1997
32. SCHEUER H, GWINNER W, HOHBACH J, et al: Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 278:F63-F74, 2000
33. ARATANI Y, KOYAMA H, NYUI S, et al: Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun 67:1828-1836, 1999
34. BRENNAN ML, ANDERSON MM, SHIH DM, et al: Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107:419-430, 2001
35. TAKIZAWA S, ARATANI Y, FUKUYAMA N, et al: Deficiency of myeloperoxidase increases infarct volume and nitrotyrosine formation in mouse brain. J Cereb Blood Flow Metab 22:50-54, 2002
36. ASKARI AT, BRENNAN ML, ZHOU X, et al: Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197:615-624, 2003
37. PETRIDES PE: Molecular genetics of peroxidase deficiency. J Mol Med 76:688-698, 1998
38. NAUSEEF WM, COGLEY M, BOCK S, PETRIDES PE: Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol 63:264-269, 1998
39. TOBLER A, SELSTED ME, MILLER CW, et al: Evidence for a pretranslational defect in hereditary and acquired myeloperoxidase deficiency. Blood 73:1980-1986, 1989
40. SELSTED ME, MILLER CW, NOVOTNY MJ, et al: Molecular analysis of myeloperoxidase deficiency shows heterogeneous patterns of the complete deficiency state manifested at the genomic, mRNA, and protein levels. Blood 82:1317-1322, 1993
41. PIEDRAITA FJ, MOLANDER RB, VANSANT G, et al: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420, 1996
42. DELEO FR, GOEDKEN M, MCCORMICK SJ, NAUSEEF WM: A novel form of hereditary myeloperoxidase deficiency linked to endoplasmic reticulum/ proteasome degradation. J Clin Invest 101:2900-2909, 1998
43. CRAMER R, SORANZO MR, DRI P, et al: Incidence of myeloperoxidase deficiency in an area of northern Italy: histochemical, biochemical and functional studies. Br J Haematol 51:81-87, 1982
44. LANZA F: Clinical manifestation of myeloperoxidase deficiency. J Mol Med 76:676-681, 1998
45. KUTTER D, DEVAQUET P, VANDERSTOCKEN G, et al: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 104:10-15, 2000
46. D'ONOFRIO G, MANCINI R, VALLONE R, et al: Acquired neutrophil myeloperoxidase deficiency: An indicator of subclinical activation of blood coagulation? Blood Cells 9:455-466, 1983
47. GERBER CE, KUCI S, ZIPFEL M, et al: Phagocytic activity and oxidative burst of granulocytes in persons with myeloperoxidase deficiency. Eur J Clin Chem Clin Biochem 34:901-908, 1996
48. ZHANG R, SHEN Z, NAUSEEF WM, HAZEN SL: Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase- deficient subjects:systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood 99:1802-1810, 2002
49. ZHANG R, BRENNAN ML, FU X, et al: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142, 2001
50. HOY A, TREGOUET D, LEININGER-MÜLLER B, et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 9:780-786, 2001
51. GRINYO JM: Role of ischemia-reperfusion injury in the development of chronic renal allograft damage. Transplant Proc 33:3741-3742, 2001
52. MELNIKOV VY, FAUBEL S, SIEGMUND B, et al. Neutrophil-independent mechanisms of caspase-1-and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110:1083-1091, 2002
53. LINAS SL, WHITTENBURG D, PARSONS PE, REPINE JE: Ischemia increases neutrophil retention and worsens acute renal failure: Role of oxygen metabolites and ICAM 1. Kidney Int 48:1584-1591, 1995
54. LLOBERAS N, TORRAS J, HERRERO-FRESNEDA I, et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 16:908-910, 2002
55. LICHT C, KRIEGESMANN E, MINOR T, et al. Influence of taurine supplementation on ischemic preservation of the isolated rat kidney. Adv Exp Med Biol 442:201-206, 1998
56. BARRY MC, KELLY CJ, ABDIH H, et al. Differential effects of lower limb revascularisation on organ injury and the role of the amino acid taurine. Eur J Vasc Endovasc Surg 13:193-201, 1997
57. GONZALEZ-FLECHA B, BOVERIS A: Mitochondrial sites of hydrogen peroxide production in reperfused rat kidney cortex. Biochim Biophys Acta 1243:361-366, 1995
58. ZULUETA JJ, SAWHNEY R, YU FS, et al: Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxiareoxygenation. Am J Physiol 272:L897-L902, 1997
59. MCKELVEY TG, HÖLLWARTH ME, GRANGER DN, et al. Mechanisms of conversion of xanthine dehydrogenase to xanthine oxidase in ischemic rat liver and kidney. Am J Physiol 254:G753-G760, 1988
60. LINAS SL, WHITTENBURG D, REPINE JE: Role of xanthine oxidase in ischemia/reperfusion injury. Am J Physiol 258:F711-F716, 1990
61. - in posthypoxic injury of renal epithelial cells. Am J Physiol 263:F251-F255, 1992
62. GRANGER DN: Role of xanthine oxidase and granulocytes in schemia-reperfusion injury. Am J Physiol Heart Circ Physiol 255:H1269-H1275, 1988
63. KOOIJ A, SCHIJNS M, FREDERIKS WM, et al: Distribution of xanthine oxidoreductase activity in human tissues - A histochemical and biochemical study. Virchows Arch 63:17-23, 1992
64. LINDER N, RAPOLA J, RAIVIO KO: Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest 79:967-974, 1999
65. MORIWAKI Y, YAMAMOTO T, SUDA M, et al: Purification and immunohistochemical tissue localization of human xanthine oxidase. Biochim Biophys Acta 1164:327-330, 1993
66. TRONCOSO P, DOMINGUEZ J, MARTINEZ L, ZAMBRANO N: Oxidative damage markers in a renal ischemic-reperfusion model: The protective effect of monoamine oxidase inhibition. Transplant Proc 27:1836-1838, 1995
67. KUNDUZOVA OR, BIANCHI P, PIZZINAT N, et al: Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J 16:1129-1131, 2002
68. NOIRI E, NAKAO A, UCHIDA K, et al: Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 281:F948-F957, 2001
69. CHATTERJEE PK, PATEL NS, KVALE EO, et al: Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int 61:862-871, 2002
70. CHATTERJEE PK, PATEL NS, SIVARAJAH A, et al: GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int 63:853-865, 2003
71. JIANG Q, HURST JK: Relative chlorinating, nitrating, and oxidizing capabilities of neutrophils determined with phagocytosable probes. J Biol Chem 272:32767-32772, 1997
72. AL-SHEBEB T, FRÖHLICH J, MAGIL AB: Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 33:498-507, 1988
73. MARSCHE G, HAMMER A, OSKOLKOVA O, et al. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 277:32172-32179, 2002
74. MALLE E, WAEG G, THIERY J, et al. Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 289:894-900, 2001
75. BRÄSEN JH, HAKKINEN T, MALLE E, et al: Patterns of oxidized epitopes, but not NF-κB expression, change during atherogenesis in WHHL rabbits. Atherosclerosis 166:13-21, 2003
76. WOENCKHAUS C, KAUFMANN A, BUSSFELD D, et al. Hypochlorite-modified LDL: chemotactic potential and chemokine induction in human monocytes. Clin Immunol Immunopathol 86:27-33, 1998
77. KOPPRASCH S, LEONHARDT W, PIETZSCH J, KUHNE H: Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. Atherosclerosis 136:315-324, 1998
78. BALDUS S, EISERICH JP, MANI A, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 108:1759-1770, 2001
79. NUSZKOWSKI A, GRÄBNER R, MARSCHE G, et al: Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem 276:14212-14221, 2001
80. MARSCHE G, LEVAK-FRANK S, QUEHENBERGER O, et al: Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J 15:1095-1097, 2001
81. JOHNSON AC, YABU JM, HANSON S, et al. Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. Am J Pathol 162:283-291, 2003
82. KOSAKA H, YONEYAMA H, ZHANG L, et al: Induction of LOX-1 and iNOS expressions by ischemia-reperfusion of rat kidney and the opposing effect of L-arginine. FASEB J 17:636-643, 2003
83. IWASHIMA Y, ETO M, HATA A, et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277:368-380, 2000
84. UENO T, KANAME S, TAKAICHI K, et al. LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats. Hypertens Res 26:117-122, 2003
85. CHIBA Y, ANDO K, FUJITA T: The protective effects of taurine against renal damage by salt loading in Dahl salt-sensitive rats. J Hypertens 20:2269-2274, 2002
86. UCHIMURA K, NAGASAKA A, HAYASHI R, et al. Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J Diabetes Complications 13:264-270, 1999
87. SATO N, KASHIMA K, TANAKA Y, et al: Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 46:133-137, 1997
88. HORIE K, MIYATA T, MAEDA K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100:2995-3004, 1997
89. TANJI N, MARKOWITZ GS, FU C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656-1666, 2000
90. TANAKA N, YONEKURA H, YAMAGISHI S, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781-25790, 2000
91. BASTA G, LAZZERINI G, MASSARO M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816-822, 2002
92. AUGUSTIN AJ, SPITZNAS M, KOCH F, et al. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ger J Ophthalmol 4:47-51, 1995
93. NEALE TJ, ULLRICH R, OJHA P, et al: Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 90:3645-3649, 1993
94. KERJASCHKI D, NEALE TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518-2526, 1996
95. MONGA G, MAZZUCCO G, CASTELLO R: Glomerular monocyte infiltration in human nephropathies:prevalence and correlation with clinical and morphological variables. Virchows Arch A Pathol Anat Histopathol 405:483-496, 1985
96. FERRARIO F, CASTIGLIONE A, COLASANTI G, et al. The detection of monocytes in human glomerulonephritis. Kidney Int 28:513-519, 1985
97. COCKWELL P, BROOKS CJ, ADU D, SAVAGE CO: Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis. Kidney Int 55:852-863, 1999
98. FALK RJ, TERRELL RS, CHARLES LA, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119, 1990
99. D'AGATI V: Antineutrophil cytoplasmic antibody and vasculitis: Much more than a disease marker. J Clin Invest 110:919-921, 2002
100. SAVAGE CO, HARPER L, HOLLAND M: New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 14:15-22, 2002
101. XIAO H, HEERINGA P, HU P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955-963, 2002
102. HARPER L, COCKWELL P, ADU D, SAVAGE CO: Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 59:1729-1738, 2001
103. HESS C, SADALLAH S, SCHIFFERLI JA: Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 96:2822-2827, 2000
104. TSE WY, WILLIAMS J, PALL A, et al. Antineutrophil cytoplasm antibody-induced neutrophil nitric oxide production is nitric oxide synthase independent. Kidney Int 59:593-600, 2001
105. EWERT BH, JENNETTE JC, FALK RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 41:375-383, 1992
106. GRIFFEN SV, CHAPMAN PT, LIANOS EA, LOCKWOOD CM: The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney Int 55:917-925, 1999
107. MOOSIG F, CSERNOK E, KUMANOVICS G, GROSS WL: Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-α). Clin Exp Immunol 122:499-503, 2000
108. KETTRITZ R, SCHEUMANN J, XU Y, et al: TNF-α-accelerated apoptosis abrogates ANCA-mediated neutrophil respiratory burst by a caspase-dependent mechanism. Kidney Int 61:502-515, 2002
109. PARK E, ALBERTI J, QUINN MR, SCHULLER-LEVIS G: Taurine chloramine inhibits the production of superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. Adv Exp Med Biol 442:177-182, 1998
110. PARK E, JIA J, QUINN MR, SCHULLER-LEVIS G: Taurine chloramine inhibits lymphocyte proliferation and decreases cytokine production in activated human leukocytes. Clin Immunol 102:179-184, 2002
111. KANAYAMA A, INOUE J, SUGITA-KONISHI Y, et al: Oxidation of Iκ-Bα at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-κB activation. J Biol Chem 277:24049-24056, 2002
112. VAN DALEN CJ, WHITEHOUSE MW, WINTERBOURN CC, KETTLE AJ: Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 327:487-492, 1997
113. CARR AC, TIJERINA T, FREI B: Vitamin C protects against and reverses specific hypochlorous acid-and chloramine-dependent modifications of low-density lipoprotein. Biochem J 346:491-499, 2000
114. LI JZ, SHARMA R, DILEEPAN KN, SAVIN VJ: Polymorphonuclear leukocytes increase glomerular albumin permeability via hypohalous acid. Kidney Int 46:1025-1030, 1994
115. DE LA CRUZ CI, RUIZ-TORRES P, DEL MORAL RG, et al: Age-related progressive renal fibrosis in rats and its prevention with ACE inhibitors and taurine. Am J Physiol Renal Physiol 278:F122-F129, 2000
116. SATO S, YAMATE J, SAITO T, et al: Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365:277-283, 2002
117. TRACHTMAN H, FUTTERWEIT S, MAESAKA J, et al: Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol 269:F429-F438, 1995
118. MCGRATH MS, KAHN JO, HERNDIER BG: Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 3:365-373, 2002
119. HANSEN A, KEMP K, KEMP E, et al. High-dose stabilized chlorite matrix WF10 prolongs cardiac xenograft survival in the hamster-to-rat model without inducing ultrastructural or biochemical signs of cardiotoxicity. Pharmacol Toxicol 89:92-95, 2001
120. SCHEMPP H, REIM M, DORNISCH K, ELSTNER EF: Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF-10. Drug Res 51:554-562, 2001